Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trialH. Miles Prince, M. D’Incan, José Antônio Sanches et al.|The Lancet|2017Cited by 580
TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targetsDavid T Yeung, Timothy P. Hughes, Michael Osborn et al.|Blood|2014Cited by 102
Twice Daily Dosing with the Highly Specific BTK Inhibitor, Bgb-3111, Achieves Complete and Continuous BTK Occupancy in Lymph Nodes, and Is Associated with Durable Responses in Patients (pts) with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)Constantine S. Tam, Andrew W. Roberts, Stephen Opat et al.|Blood|2016Cited by 37
Severe hemolysis and transfusion reactions after treatment with BGB-3111 and PD-1 antibody for Waldenström macroglobulinemiaJad Othman, Robin Gasiorowski, Emma Verner et al.|Haematologica|2018Cited by 12